Advanced search
Publication Cover
Modern Rheumatology Case Reports Volume 3, 2019 - Issue 1
Journal homepage
1,913
Views
1
CrossRef citations to date
0
Altmetric
Case Report

Tocilizumab prevents renal function of a patient with diabetic kidney disease: case report

Naoya ToriuNephrology Center and Department of Rheumatology, Toranomon Hospital, Tokyo, Japan; Correspondence[email protected]
ORCID Iconhttp://orcid.org/0000-0002-3712-6331
ORCID Icon,
Masayuki YamanouchiNephrology Center and Department of Rheumatology, Toranomon Hospital, Tokyo, Japan;
,
Rikako HiramatsuNephrology Center and Department of Rheumatology, Toranomon Hospital, Tokyo, Japan;
,
Noriko HayamiNephrology Center and Department of Rheumatology, Toranomon Hospital, Tokyo, Japan;
,
Junichi HoshinoNephrology Center and Department of Rheumatology, Toranomon Hospital, Tokyo, Japan;
,
Akinari SekineNephrology Center and Department of Rheumatology, Toranomon Hospital, Tokyo, Japan;
,
Masahiro KawadaNephrology Center and Department of Rheumatology, Toranomon Hospital, Tokyo, Japan;
,
Eiko HasegawaNephrology Center and Department of Rheumatology, Toranomon Hospital, Tokyo, Japan;
,
Tatsuya SuwabeNephrology Center and Department of Rheumatology, Toranomon Hospital, Tokyo, Japan;
,
Keiichi SumidaNephrology Center and Department of Rheumatology, Toranomon Hospital, Tokyo, Japan;
,
Naoki SawaNephrology Center and Department of Rheumatology, Toranomon Hospital, Tokyo, Japan;
,
Kenmei TakaichiNephrology Center and Department of Rheumatology, Toranomon Hospital, Tokyo, Japan; ;Okinaka Memorial Institute for Medical Research, Tokyo, Japan;
,
Motoko YanagitaDepartment of Nephrology, Kyoto University Graduate School of Medicine, Kyoto, Japan
&
Yoshifumi UbaraNephrology Center and Department of Rheumatology, Toranomon Hospital, Tokyo, Japan; ;Okinaka Memorial Institute for Medical Research, Tokyo, Japan; Correspondence[email protected]
 show all
Pages 53-56 | Received 08 Feb 2018, Accepted 15 May 2018, Published online: 10 Sep 2018

References

  • Alicic RZ, Rooney MT, Tuttle KR. Diabetic kidney disease: challenges, progress, and possibilities. Clin J Am Soc Nephrol. 2017;12:2032–2045.
  • Pavkov ME, Knowler WC, Bennett PH, et al. Increasing incidence of proteinuria and declining incidence of end-stage renal disease in diabetic Pima Indians. Kidney Int. 2006;70:1840–1846.
  • de Zeeuw D, Akizawa T, Audhya P, et al. Bardoxolone methyl in type 2 diabetes and stage 4 chronic kidney disease. N Engl J Med. 2013;369:2492–2503.
  • Navarro-Gonzalez JF, Mora-Fernandez C. The role of inflammatory cytokines in diabetic nephropathy. J Am Soc Nephrol. 2008;19:433–442.
  • Su H, Lei CT, Zhang C. Interleukin-6 signaling pathway and its role in kidney disease: an update. Front Immunol. 2017;8:405.
  • Dotson S, Freeman R, Failing HJ, et al. Hypoglycemia increases serum interleukin-6 levels in healthy men and women. Diabetes Care. 2008;31:1222–1223.
  • Malenica M, Silar M, Dujic T, et al. Importance of inflammatory markers and IL-6 for diagnosis and follow up of patients with type 2 diabetes mellitus. Med Glas (Zenica). 2017;14:169–175.
  • Wegner M, Araszkiewicz A, Piorunska-Stolzmann M, et al. Association between IL-6 concentration and diabetes-related variables in DM1 patients with and without microvascular complications. Inflammation. 2013;36:723–728.
  • Dalla Vestra M. Acute-phase markers of inflammation and glomerular structure in patients with type 2 diabetes. J Am Soc Nephrol. 2005;16:S78–S82.
  • Sumida K, Molnar MZ, Potukuchi PK, et al. Treatment of rheumatoid arthritis with biologic agents lowers the risk of incident chronic kidney disease. Kidney Int. 2018;93:1207–1216.
  • Moriwaki Y, Inokuchi T, Yamamoto A, et al. Effect of TNF-alpha inhibition on urinary albumin excretion in experimental diabetic rats. Acta Diabetol. 2007;44:215–218.
  • Utimura R, Fujihara CK, Mattar AL, et al. Mycophenolate mofetil prevents the development of glomerular injury in experimental diabetes. Kidney Int. 2003;63:209–216.
  • Lei CT, Su H, Ye C, et al. The classic signalling and trans-signalling of interleukin-6 are both injurious in podocyte under high glucose exposure. J Cell Mol Med. 2017;22:251–260.
  • Oshima Y, Hoshino J, Suwabe T, et al. Multicentric Castleman's disease associated with IgA vasculitis (Henoch-Schonlein purpura) responding well to tocilizumab: a case report. Clin Rheumatol. 2017;36:729–733.
  • Iijima T, Hoshino J, Suwabe T, et al. Tocilizumab for AA amyloidosis after treatment of multicentric Castleman disease with steroids, chemotherapy and rituximab for over 20 years. Intern Med. 2015;54:3215–3219.
  • Iijima T, Suwabe T, Sumida K, et al. Tocilizumab improves systemic rheumatoid vasculitis with necrotizing crescentic glomerulonephritis. Modern Rheumatol. 2015;25:138–142.
  • Nishimoto N, Kanakura Y, Aozasa K, et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 2005;106:2627–2632.
  • Okuda Y, Ohnishi M, Matoba K, et al. Comparison of the clinical utility of tocilizumab and anti-TNF therapy in AA amyloidosis complicating rheumatic diseases. Modern Rheumatol. 2014;24:137–143.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.